Alcon affirmed fiscal year 2025 adjusted earnings of $3.05-$3.15 versus consensus of $3.12. The company lowered 2025 sales guidance from $10.4 billion-$10.5 billion to $10.3 billion-$10.4 billion, ...

The analysts cut its rating on Alcon shares to “neutral” from “overweight” and lowered its price target to SFr 62.8 for June 2027, down from SFr 94.7 for June 2026. The reduced target reflects lower ...

J.P. Morgan downgraded Alcon (NYSE:ALC) to Neutral from Overweight on Thursday after the Swiss maker of intraocular lenses reported Q2 2025 results falling short of Street forecasts for revenue ...

Alcon AG (NYSE:ALC) saw its stock fall more than 2% on Thursday following a rating cut by J.P. Morgan, citing disappointing quarterly performance and reduced visibility on earnings. David Adlington, ...

JP Morgan’s European desk has upgraded Alcon (ALC) to overweight, commenting that concerns about growth in the implantables market is likely to be “short-lived.” Read more here.

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives.

In addition, two months ago, Alcon secured a majority stake in clinical-stage company Aurion Biotech. In February, Alcon reported 2024 revenue at $9.8 billion, which was up 5% from the prior year.

Under the terms of the agreement announced Tuesday, Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, in a deal valued at approximately $1.5 billion.

Biotech Alcon gains upper hand in Aurion power struggle via majority stake, removing CEO By James Waldron Mar 27, 2025 9:23am Aurion Biotech Alcon investor lawsuit mergers and acquisitions ...